INTERFERON-ALPHA, 5-FU AND PREDNISONE IN METASTATIC RENAL-CELL CARCINOMA - A PHASE-II STUDY

被引:25
作者
HAARSTAD, H
JACOBSEN, AB
SCHJOLSETH, SA
RISBERG, T
FOSSA, SD
机构
[1] NORWEGIAN RADIUM HOSP,DEPT MED ONCOL & RADIOTHERAPY,N-0310 OSLO,NORWAY
[2] REG HOSP TRONDHEIM,DEPT ONCOL,TRONDHEIM,NORWAY
[3] CENT HOSP LILLEHAMMER,DEPT INTERNAL MED,LILLEHAMMER,GERMANY
[4] REG HOSP TROMSO,DEPT ONCOL,TROMSO,NORWAY
关键词
INTERFERON-ALPHA; 5-FU; PREDNISONE; RENAL CELL CARCINOMA; RESPONSE RATE; ADVERSE EFFECTS;
D O I
10.1093/oxfordjournals.annonc.a058801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Due to the possibility of a synergistic effect between Interferon (IFN-alpha) and 5-Fluorouracil (5-FU), a phase II trial was conducted in metastatic renal cell carcinoma (MRCC) combining recombinant IFN-alpha, 5-FU and prednisone. Prednisone has been shown to decrease IFN-alpha-related toxicity without reducing the response rate. Patients and methods: Thirty-one patients with measurable MRCC were entered into the trial; 16 of them had lung metastases only. In 26 patients (nos. 6-31) the following dose schedule was applied during an 8-week treatment cycle: IFN-alpha (Roferon(R), Roche, Basel, Switzerland): 12 x 10(6)U s.c. 3 times weekly; Days 1-5: 5-FU: 600 mg/m2/day continuous i.v. infusion; Weeks 3-8: 5-FU 600 mg/m2 X 1 weekly (bolus i.v.); prednisone: 10 mg x 2 per os daily for 2 weeks, and thereafter 5 mg x 2. In the first 5 patients higher doses of 5-FU led to unacceptable toxicity and subsequent dose alteration of the trial schedule. All 31 patients were evaluable for response. Seventy treatment cycles were given. Results: One complete and 6 partial responses were observed (response rate: 23%, 95% CI: 10%-41%), with a median response duration of 11 months. Except in one patient, hematological toxicity was confined to grades I and II. Eight patients developed grade III oral mucositis. Adverse cardiac events were observed in 3 patients. Dose modifications of 5-FU were necessary in 16 cycles. The IFN-alpha doses were transiently reduced during 8 cycles. Conclusion: The assessed combination of IFN-alpha, 5-FU and prednisone is moderately active in MRCC, with response rates similar to those seen in patients on IFN-alpha monotherapy. The latter treatment approach seems preferable, as 5-FU-related toxicity (mucositis, cardiac toxicity) is averted.
引用
收藏
页码:245 / 248
页数:4
相关论文
共 50 条
  • [21] A PHASE-II STUDY OF THE CONTINUOUS INTRAVENOUS-INFUSION OF INTERLEUKIN-6 FOR METASTATIC RENAL-CELL CARCINOMA
    WEISS, GR
    MARGOLIN, KA
    SZNOL, M
    ATKINS, MB
    OLEKSOWICZ, L
    ISAACS, R
    SOSMAN, JA
    DOROSHOW, JH
    TREHU, EG
    DUTCHER, JP
    FISHER, RI
    JOURNAL OF IMMUNOTHERAPY, 1995, 18 (01): : 52 - 56
  • [22] RENAL-CELL CARCINOMA WITH SUBCUTANEOUS INJECTIONS OF INTERLEUKIN-2 AND INTERFERON-ALPHA
    HOFMOCKEL, G
    THEISS, M
    BUSSEN, D
    WIRTH, MP
    FROHMULLER, HGW
    UROLOGE-AUSGABE A, 1994, 33 (05): : 434 - 439
  • [23] Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study
    Kankuri-tammilehto, Minna
    Perasto, Laura
    Pyrhonen, Seppo
    Salminen, Eeva
    ANTICANCER RESEARCH, 2023, 43 (06) : 2645 - 2657
  • [24] Cyclic interferon alpha treatment in metastatic renal cell carcinoma: Results of a phase II study and review of the literature
    Hofmockel, G
    Tack, W
    Frohmuller, HGW
    UROLOGIA INTERNATIONALIS, 1997, 58 (01) : 8 - 12
  • [25] A PHASE-II TRIAL OF INTERFERON ALPHA-2A PLUS FLUOROURACIL IN ADVANCED RENAL-CELL CARCINOMA - A HOOSIER ONCOLOGY GROUP-STUDY
    MURPHY, BR
    RYNARD, SM
    EINHORN, LH
    LOEHRER, PJ
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (03) : 225 - 230
  • [26] INTERFERON-ALPHA ANTIBODIES IN PATIENTS WITH RENAL-CELL CARCINOMA TREATED WITH RECOMBINANT INTERFERON-ALPHA-2A IN AN ADJUVANT MULTICENTER TRIAL
    PRUMMER, O
    ALEFELDER, J
    BERTELS, C
    GRAFF, J
    HAUPT, G
    PASTOR, J
    BUTTGEN, A
    DROST, KH
    FENSTERER, M
    TUNN, UW
    FROHNEBERG, D
    HAUTMANN, R
    WENDEROTH, U
    BOECKMANN, W
    JONAS, D
    SCHULDE, H
    HARTMANN, H
    LEYENDECKER, K
    SPARWASSER, H
    EISENBERGER, F
    HEINZL, R
    LUTZ, K
    WELLINGER, D
    FISCHER, C
    HALLWACHS, O
    STOCK, U
    HUHN, D
    MATHEW, M
    NAGEL, R
    VANHERPE, H
    LOHMER, H
    MELCHIOR, HJ
    HOFMANN, J
    SCHNEIDER, W
    SCHRAUDENBACH, L
    BRAUNCHAURASIA, R
    PLANZ, K
    VAHLENSIECK, W
    WINTER, P
    FORSTER, P
    WIELAND, W
    HASUN, R
    MARBERGER, M
    BRANDL, H
    CHAUSSY, C
    LEESER, C
    MRSTIK, C
    STOGERMAYER, F
    BRANDES, V
    BUCHSEL, HP
    CANCER, 1993, 71 (05) : 1828 - 1834
  • [27] A PHASE-II STUDY OF VINBLASTINE IN COMBINATION WITH ACRIVASTINE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    BERLIN, J
    KING, AC
    TUTSCH, K
    FINDLAY, JW
    KOHLER, P
    COLLIER, M
    CLENDENINN, NJ
    WILDING, G
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) : 137 - 141
  • [28] PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    LAW, TM
    ILSON, DH
    MOTZER, RJ
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) : 143 - 145
  • [29] LIMITED EFFICACY OF INTERFERON-ALPHA AND VINBLASTINE AS 2ND LINE BIOCHEMOTHERAPY REGIMEN IN PATIENTS WITH PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA
    HANNINEN, EL
    FENNER, M
    KIRCHNER, H
    DECKERT, M
    DUENSING, S
    MENZEL, T
    POLIWODA, H
    ATZPODIEN, J
    CANCER BIOTHERAPY, 1993, 8 (04): : 301 - 306
  • [30] TRIMETREXATE IN ADVANCED RENAL-CELL CARCINOMA - AN ECOG PHASE-II TRIAL
    WITTE, RS
    ELSON, P
    BRYAN, GT
    TRUMP, DL
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (01) : 51 - 54